Cardiol Therapeutics Inc. (NASDAQ:CRDL) Forecasted to Earn Q2 2024 Earnings of ($0.09) Per Share

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Equities research analysts at Roth Capital issued their Q2 2024 EPS estimates for Cardiol Therapeutics in a research note issued to investors on Wednesday, June 26th. Roth Capital analyst J. Wittes anticipates that the company will post earnings per share of ($0.09) for the quarter. Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. Roth Capital also issued estimates for Cardiol Therapeutics’ Q3 2024 earnings at ($0.09) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.35) EPS, Q1 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.39) EPS.

Cardiol Therapeutics (NASDAQ:CRDL) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04).

CRDL has been the topic of a number of other research reports. Canaccord Genuity Group raised their price objective on shares of Cardiol Therapeutics from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Thursday, May 23rd. Roth Mkm initiated coverage on shares of Cardiol Therapeutics in a research report on Wednesday. They set a “buy” rating and a $10.00 price objective for the company. Canaccord Genuity Group raised their target price on Cardiol Therapeutics from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Thursday, May 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Cardiol Therapeutics in a report on Friday, June 14th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $7.60.

Cardiol Therapeutics Trading Up 1.0 %

Shares of NASDAQ:CRDL opened at $2.02 on Friday. Cardiol Therapeutics has a 52-week low of $0.66 and a 52-week high of $3.12. The stock has a market capitalization of $139.38 million, a price-to-earnings ratio of -5.77 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.81 and a current ratio of 2.81. The stock’s 50-day simple moving average is $2.21 and its two-hundred day simple moving average is $1.65.

Institutional Trading of Cardiol Therapeutics

A hedge fund recently raised its stake in Cardiol Therapeutics stock. Laird Norton Trust Company LLC boosted its holdings in Cardiol Therapeutics Inc. (NASDAQ:CRDL) by 63.1% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 100,000 shares of the company’s stock after buying an additional 38,673 shares during the period. Laird Norton Trust Company LLC owned 0.15% of Cardiol Therapeutics worth $90,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 12.49% of the company’s stock.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.